# Efficacy of Intracavernosal as add-on Therapy to Sildenafil 100 mg on Demand Compared to Sildenafil 100 mg on Demand for the Treatment of Erectile Dysfunction (ED) Not Sufficiently Responsive to Standard Therapy With Phosphodiesterase Type 5 Inhibitors

> **NCT05196308** · PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 226 (actual)

## Conditions studied

- Erectile Dysfunction

## Interventions

- **DRUG:** Investigational product administration Xeomin® (MERZ PHARMACEUTICALS GMBH)
- **DRUG:** Placebo administration

## Key facts

- **NCT ID:** NCT05196308
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-18
- **Primary completion:** 2024-07-23
- **Final completion:** 2024-11-15
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05196308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05196308, "Efficacy of Intracavernosal as add-on Therapy to Sildenafil 100 mg on Demand Compared to Sildenafil 100 mg on Demand for the Treatment of Erectile Dysfunction (ED) Not Sufficiently Responsive to Standard Therapy With Phosphodiesterase Type 5 Inhibitors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05196308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*